Pharmacological therapies for early and long-term recovery in disorders of consciousness: current knowledge and promising avenues DOI Creative Commons

Rosalie Girard Pepin,

Fatemeh Seyfzadehdarabad, David Williamson

et al.

Expert Review of Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 21

Published: May 7, 2025

Disorders of consciousness (DoC) are characterized by impaired arousal and/or awareness, ranging from coma to unresponsive wakefulness syndrome, minimally conscious state, and cognitive motor dissociation. Pharmacological treatment options remain limited, complicated the heterogeneity etiologies, such as traumatic brain injury, stroke, infections. The lack rigorous clinical trials has led off-label use treatments, often without clear mechanistic understanding, posing challenges for effective patient care. In this perspective, authors report on key studies concerning effectiveness pharmacological interventions, including dopaminergic GABAergic agents, antidepressants, statins, anticonvulsants, in promoting recovery DoC. Robust longitudinal needed, with priority given early subacute phase intervention. Outcomes should be better defined, considering immediate responses medication while also increasing emphasis long-term quality life. Unified functional frameworks needed guide research foster collaboration. Furthermore, a shift toward personalized medicine would benefit heterogeneous population. Moving forward, assessing efficacy more unconventional or 'paradoxical' plans will essential. expect an increased AI tools identify factors that best predict responses.

Language: Английский

Psilocybin for disorders of consciousness: a case-report study DOI Creative Commons
Paolo Cardone, Pablo Núñez, Naji Alnagger

et al.

Clinical Neurophysiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

1
Pharmacological therapies for early and long-term recovery in disorders of consciousness: current knowledge and promising avenues DOI Creative Commons

Rosalie Girard Pepin,

Fatemeh Seyfzadehdarabad, David Williamson

et al.

Expert Review of Neurotherapeutics, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 21

Published: May 7, 2025

Disorders of consciousness (DoC) are characterized by impaired arousal and/or awareness, ranging from coma to unresponsive wakefulness syndrome, minimally conscious state, and cognitive motor dissociation. Pharmacological treatment options remain limited, complicated the heterogeneity etiologies, such as traumatic brain injury, stroke, infections. The lack rigorous clinical trials has led off-label use treatments, often without clear mechanistic understanding, posing challenges for effective patient care. In this perspective, authors report on key studies concerning effectiveness pharmacological interventions, including dopaminergic GABAergic agents, antidepressants, statins, anticonvulsants, in promoting recovery DoC. Robust longitudinal needed, with priority given early subacute phase intervention. Outcomes should be better defined, considering immediate responses medication while also increasing emphasis long-term quality life. Unified functional frameworks needed guide research foster collaboration. Furthermore, a shift toward personalized medicine would benefit heterogeneous population. Moving forward, assessing efficacy more unconventional or 'paradoxical' plans will essential. expect an increased AI tools identify factors that best predict responses.

Language: Английский

Citations

0